On November 20, Nathan McNally, Co-founder and Project Director of the UK P4 Precision Medicine Accelerator; Alexander Murer, Representative of the Kilobaser Austrian Genetic Testing Project; and Lynn Huang, International Project Director of GlobalTech IP UK Innovation Partnership Alliance, visited Shenzhen Cell Valley for exchange. Shenzhen Cell Valley's Chairman Shi Yuanyuan, Deputy General Manager Xiang Hua, R&D Department Head Zhao Lijun, Marketing Department Head Sun Rui, General Office Director Luan Zhishi, and Senior R&D Scientist Zhu Wenxiang warmly received them. Dr. Ivan O. Rosas, Professor from Baylor College of Medicine who was visiting Cell Valley, also participated in the meeting. Both parties engaged in discussions on expanding cell and gene therapy services to overseas markets such as Europe.

First, led by Director Luan Zhishi and Department Head Zhao Lijun, the European team visited the Smart Exhibition Hall, gaining a preliminary understanding of the company's development background, corporate strength, product pipelines, and planning layout.

During the symposium, Chairman Shi Yuanyuan stated that the global cell and gene therapy market is showing rapid growth, and conducted a comparative analysis of the current status and industrial production of cell therapy vector technologies, pointing out that retroviral vectors possess favorable cost advantages and market prospects. As the only one-stop service platform in China mastering industrial-grade retroviral vector production processes, how Shenzhen Cell Valley can better serve the whole country and even the world, achieve overseas market expansion of innovative drugs, and benefit patients globally is an important strategic layout aligned with industry trends and demands. Nathan McNally stated that the UK has always been at the forefront of global innovation. Relying on long-term government support, profound basic research, an open innovation atmosphere, and abundant talent resources, it has become one of the best places in the world for developing, manufacturing, and commercializing cell and gene therapies. Lynn Huang mentioned that the UK government and top industry institutions also support numerous innovation programs, assisting in the R&D and clinical implementation of CGT products and empowering highly innovative CGT enterprises through incubation.

This exchange visit has laid a solid foundation for future cooperation and communication between the two parties, providing a favorable opportunity and platform for business expansion and product technology promotion, forming synergy between domestic and international efforts, and laying the groundwork for achieving new development prospects.